

# Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)

Technology appraisal guidance

Published: 25 June 2025

[www.nice.org.uk/guidance/ta1078](https://www.nice.org.uk/guidance/ta1078)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of fosdenopterin for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the appraisal. The company's decision reflects the challenge of reaching an economically sustainable route to reimbursement.

## Information

If NHS organisations wish to consider fosdenopterin for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7092-6